Checkpoint inhibitors in bladder and renal cancers: results and perspectives

被引：20

作者：

Aoun, Fouad ^{[1
]}

Kourie, Hampig R. ^{[2
]}

Sideris, Spyridon ^{[2
]}

Roumeguere, Thierry ^{[3
]}

van Velthoven, Roland ^{[1
]}

Gil, Thierry

机构：

[1] Inst Jules Bordet, Dept Urol, B-1000 Brussels, Belgium

[2] Inst Jules Bordet, Dept Oncol, B-1000 Brussels, Belgium

[3] Erasme Univ Hosp, Dept Urol, B-1070 Brussels, Belgium

来源：

IMMUNOTHERAPY | 2015年 / 7卷 / 12期

关键词：

bladder cancer; checkpoint inhibitors; CTLA4; immunotherapy; PD1/PDL1; renal cell carcinoma; TRANSITIONAL CELL-CARCINOMA; CLINICAL ACTIVITY; INTERFERON-ALPHA; TUMOR-CELL; HLA-G; BLOCKADE; IMMUNOTHERAPY; SURVIVAL; ANTIBODY; NIVOLUMAB;

D O I：

10.2217/imt.15.91

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The field of immunotherapy in urinary malignancy is expanding in several directions and checkpoint inhibitors are leading the way. The aim of this report is to highlight the efficacy and safety profile of the two classes of molecules, anti-cytotoxic T-lymphocyte antigen-4 and anti-programmed death receptor-1/programmed death ligand type 1, that are under investigation and represent potential candidates to be used in the near future for the management of bladder and renal cell cancer. The preliminary results as well as the future perspectives of this novel immunotherapy are analyzed. Novel immune checkpoint targets are reviewed as well.

引用

页码：1259 / 1271

页数：13

共 50 条

[21] Immune Checkpoint Inhibitors for Pediatric Cancers: Is It Still a Stalemate?
Jaing, Tang-Her
Wang, Yi-Lun
Chiu, Chia-Chi
[J]. PHARMACEUTICALS, 2024, 17 (08)
[22] Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers
Li, Meng
Kaili, Denis
Shi, Lei
[J]. WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 14 (01) : 19 - 37
[23] Treatment of advanced urogenital cancers with immune checkpoint inhibitors
Jung, Eun Hee
Kim, Se Hyun
[J]. JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2021, 64 (05): : 349 - 357
[24] Safety of checkpoint inhibitors in older patients with genitourinary cancers
Ramnaraign, Brian Hemendra
Patel, Neil Jigish
Chatzkel, Jonathan Alexander
Hitchcock, Kathryn
Zlotecki, Robert
O'Malley, Padraic
Crispen, Paul
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[25] Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
Shen, Pan
Han, Liang
Ba, Xin
Qin, Kai
Tu, Shenghao
[J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
[26] Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers
Kim, Bum Jun
Jang, Hyun Joo
Kim, Hyeong Su
Kim, Jung Han
[J]. JOURNAL OF CANCER, 2017, 8 (08): : 1460 - 1465
[27] Immune checkpoint inhibitors in patients with cancers of unknown primary
Rassy, Elie
Karam, Elias
Adeleke, Sola
Okoli, Somto
Galante, Joao
Boussios, Stergios
Pavlidis, Nicholas
[J]. EUROPEAN JOURNAL OF CANCER, 2023, 195
[28] The emerging role of checkpoint inhibitors for rare genitourinary cancers
Jeanny B. Aragon-Ching
[J]. Nature Reviews Urology, 2021, 18 : 133 - 134
[29] The emerging role of checkpoint inhibitors for rare genitourinary cancers
Aragon-Ching, Jeanny B.
[J]. NATURE REVIEWS UROLOGY, 2021, 18 (03) : 133 - 134
[30] Overall and progression free survival in patients with acute or chronic renal failure treated with checkpoint inhibitors for renal or urinary tract cancers
Seydel, F.
Zeier, M.
Holland-Letz, T.
Jaeger, D.
Duensing, S.
Hohenfellner, M.
Zschaebitz, S.
Delecluse, S.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 194 - 194

← 1 2 3 4 5 →